Pinned post
I'm grateful and humbled to be featured on one of the covers of this year’s Forbes 400 issue.
In my interview, I shared that Breyer Capital is especially energized by the intersection of AI and the life sciences. Healthcare is at an inflection point: scientific discovery is accelerating, yet the systems of care have not kept pace. The gap between what’s possible and what’s practiced is widening, and that dislocation represents one of the defining opportunities of our time.
One example of this transformation is OpenEvidence, which this week announced a $200 million financing at a $6 billion valuation led by Google Ventures. Open Evidence now supports over 15 million clinical consultations each month, empowering physicians with trusted, evidence-based insights from leading medical journals.
At Breyer Capital, we invest where science, computation, and care converge. Breakthroughs in AI, precision medicine, and data infrastructure are reshaping how healthcare is delivered, measured, and paid for. Our goal isn’t to optimize broken systems, but to help build new ones: rearchitecting the clinical stack, compressing biomedical time, and creating evidence frameworks that learn in real time.
Thank you to Forbes for the recognition, and to the extraordinary scientists, clinicians, and entrepreneurs who continue to show us what the future of health can look like.
In my interview, I shared that Breyer Capital is especially energized by the intersection of AI and the life sciences. Healthcare is at an inflection point: scientific discovery is accelerating, yet the systems of care have not kept pace. The gap between what’s possible and what’s practiced is widening, and that dislocation represents one of the defining opportunities of our time.
One example of this transformation is OpenEvidence, which this week announced a $200 million financing at a $6 billion valuation led by Google Ventures. Open Evidence now supports over 15 million clinical consultations each month, empowering physicians with trusted, evidence-based insights from leading medical journals.
At Breyer Capital, we invest where science, computation, and care converge. Breakthroughs in AI, precision medicine, and data infrastructure are reshaping how healthcare is delivered, measured, and paid for. Our goal isn’t to optimize broken systems, but to help build new ones: rearchitecting the clinical stack, compressing biomedical time, and creating evidence frameworks that learn in real time.
Thank you to Forbes for the recognition, and to the extraordinary scientists, clinicians, and entrepreneurs who continue to show us what the future of health can look like.